Raman Pharma is a UK based MHRA and VMD Licensed Wholesaler supplying to the Human and Veterinary Market. We are a family run company ambitiously changing the face of the Pharmaceutical and Veterinary Market alike in order to serve the needs of our customers and their patients.
Our Philosophy and business are structured around the requirements of our customers and we are committed to giving them our upmost attention and care. We believe in delivering quality and value to our customers wherever they may be.
The Herbal Horse and Pet is a South African manufacturer of a very innovative range of supplements for horses, dogs and cats. Their philosophy of using a large number of different ingredients in small amounts mimics nature in that the healing effect of the ingredients is maximised while undesirable side-effects are minimised. These unique formulations, in conjunction with 21st century scientific research and techniques are what they call “cutting edge nature”.
They are manufactured in a GMP Compliant Factory and has a large following from riders and pet owners across the world. Please follow the link to the website – www.theherbalhorse.co.uk to see all the amazing blogs and the ability to purchase these products online. The Equine and Pet Range were introduced to the UK Market in September 2014 by Raman Pharma to give the UK a taste of the future in equine and companion animal nutritional supplements.
"Fantastic service, Really helpful & always able to source products that we need at very competitive prices. Would thoroughly recommend to any Veterinary Practice"
"Raman Pharma have been invaluable in sourcing drugs that are out of stock elsewhere. Delivery is rapid, costs are good and the customer service provided by Dhruv is excellent. I would definitely recommend this company and its services to others."
Community pharmacy contractors can now access an online recording of PSNC a recent Serious Shortage Protocols (SSPs) webinar. Over 600 people registered for yesterday’s webinar presented by Gordon Hockey (PSNC Director of Operations and Support) and Suraj Shah (PSNC Drug Tariff and Reimbursement Manager). During the webinar, Gordon explained what an SSP is, clarified situations...
Department of Health and Social Care (DHSC) has today granted the following list of price concessions: Drug Pack size Price Concession Alverine 60mg capsules 100 £9.80 Bumetanide 1mg tablets 28 £1.65 Cefalexin 250mg/5ml oral suspension 100ml £1.95 Celecoxib 200mg capsules 30 £9.43 Diamorphine 10mg powder for solution for injection ampoules 5 £16.56 Diamorphine 30mg powder...
Sanofi are currently experiencing difficulties ensuring sufficient product availability for normal supply to pharmacies. Sanofi say ‘The problem was caused by a change in our UK logistics provider and an unexpected technical issue with one of their IT systems.’ Sanofi expect product availability will be back to normal within two weeks and ask that pharmacy teams...
Date issued: 17th July 2019 A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 12 Issue 12 July 2019) has been published and includes articles on: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease Tocilizumab (RoActemra): rare...
Public Health England, NHS England and NHS Improvement have issued a letter to general practices and community pharmacy contractors regarding the supply of quadrivalent flu vaccines. Manufacturers of quadrivalent flu vaccines have informed them that the delayed World Health Organization recommendation on vaccine strain has had an impact on their vaccine supply. Sanofi Pasteur has...
The Government announced last month that it is pushing back next year’s Early May Bank Holiday by a few days to Friday 8th May 2020. The move has been made to coincide with the 75th anniversary of the Victory in Europe (VE) Day, which formally marked the end of World War II. Community pharmacies do not...
PSNC’s Regulations and Support Team are often asked questions about the requirements in the terms of service relating to opening hours. This briefing contains a quick reference guide for 2020. PSNC Briefing 025/19: Contract Factsheet – Pharmacy opening hours in 2020 (July 2019) If you have queries on this PSNC Briefing or you require more...
Kyowa Kirin, the sole manufacturers of Nardil (phenelzine sulfate) 15mg tablets, are currently experiencing temporary disruptions. Kyowa Kirin, the main supplier of Nardil (phenelzine sulfate) 15mg tablets have advised a resupply date of end of October 2019 Supplies are available from specialist importers on an ‘unlicensed’ basis. Ensure that where a prescriber wishes you to...
GlaxoSmithKline (GSK) and Pinewood, the manufacturers of Salbutamol 2mg/5ml syrup, are currently experiencing temporary disruptions. GSK, the main supplier of Salbutamol 2mg/5ml syrup (Ventolin) have advised a resupply date of early August 2019 Pinewood are long term out of stock due to manufacturing issues and are currently unable to advise a resupply date. Supplies are...
Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack size Price Concession Betahistine 8mg tablets 84 £1.37 Betahistine 16mg tablets 84 £2.50 Ibandronic acid 150mg tablets 1 £9.95 Losartan 12.5mg tablets 28 £3.82 Pantoprazole 40mg gastro-resistant tablets 28 £3.85 Prednisolone 5mg tablets 28 £2.25 Prednisolone...
Guidance on how to get an e-cigarette on the market in the UK, including the notification scheme and reporting problems with e-cigarettes.
Annual report of the Human Medicines Regulations 2012 Advisory Bodies - the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission
This document contains the MHRA annual report and accounts 2018 to 2019.
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor the Commission on Human Medicines.
Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.
Avoid treatment with febuxostat in patients with pre-existing major cardiovascular disease (for example, myocardial infarction, stroke, or unstable angina), unless no other therapy options are appropriate. Findings from a phase 4 clinical study (the CARES study) in patients with gout and a history of major cardiovascular disease show a higher risk for cardiovascular-related death and for all-cause mortality in patients assigned to febuxostat than in those assigned to allopurinol.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be measured before starting treatment with tocilizumab and monitored every 4–8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter. Serious liver injury has been reported on treatment with tocilizumab from 2 weeks to more than 5 years after initiation.
MHRA has received a small number of reports suggesting lack of efficacy (thromboembolic events) in patients taking 15 mg or 20 mg rivaroxaban on an empty stomach; remind patients to take 15 mg or 20 mg rivaroxaban tablets with food.
Letters were sent about Myocrisin (sodium aurothiomalate), Cerliponase alfa (Brineura▼), Darzalex▼(daratumumab), retinoids▼, and febuxostat (Adenuric). A recall alert was issued for medicines that were taken out of the regulated medicines supply chain during distribution. Other alerts were issued about paracetamol tablets, docetaxel injection, Baxter potassium-chloride-containing intravenous infusions, and Emerade adrenaline auto-injectors.
An alert was issued about Dialog+ haemodialysis machines.
The number of applications pending, refused and granted for the early access to medicines scheme (EAMS).
The Medicines and Healthcare products Regulatory Agency (MHRA) has today launched a 12-week consultation on how to best engage and involve patients in the Agency’s work.
We are reviewing our approach to how we engage and involve patients in the work of the Medicines and Healthcare products Regulatory Agency (MHRA).
Summary List of field safety notices (FSNs) from medical device manufacturers from 8 to 12 July 2019.
EAMS scientific opinion given to Merck Serono Ltd in the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).
These Regulations (which come into force immediately before exit day) are made to correct drafting defects and omissions in the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775) and the Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/791). This is to ensure that the published policy in relation to the regulation of human medicines and medical devices in a no deal EU exit scenario is properly reflected in those instruments. Those instruments, which come into force on exit day, amend the Human Medicines Regulations 2012 (S.I. 2012/1916 – “HMRs”), associated Medicines (Fees) Regulations 2016 and the Medical Devices Regulations 2002 (S.I. 2002/618 – “MDRs”) to ensure they are fit for purpose in a no deal EU exit.
This privacy notice describes how we collect and use your personal information, in accordance with the Data Protection Act and the General Data Protection Regulation.
Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.
Marketing authorisations granted in June 2019
Parallel import licenses granted in June 2019
The Veterinary Products Committee (VPC) is looking to appoint four new members.
This document contains the following information: Veterinary Medicines Directorate annual report and accounts 2018 to 2019.
How to legally run a business that deals with the wholesale of animal medicines (veterinary medicinal products) and the WDA Register.
Reported problems with the supply of an animal medicine and the date when the issue is expected to be resolved.
How to comply with the exemption from the Veterinary Medicines Regulations that allow certain animal medicines to be sold without an authorisation.
Events VMD will be attending, hosting or participating in to support and advise industry and stakeholders.
The VMD wishes to make companies aware that fenbendazole is no longer permitted for use in pigeons under Schedule 6 (Exemptions for small pet animals) of the Veterinary Medicines Regulations (VMR) 2013.
Invitation to attend the joint VMD, VPC and Industry Information event for the pharmaceutical industry on Wednesday 25 September 2019
Residues of veterinary medicines in food 2019 surveillance results.
Residues of veterinary medicines in food 2018 surveillance results.
Details of seizure notice issued to Mr Thompson, Maidstone, Kent.
A summary of results from surveillance work carried out by the VMD's pharmacovigilance team concerning reported adverse events.
A review of adverse events following the use of veterinary medicines reported in 2017.
Reporting against VMD published standards up to 31 May 2019.
For a marketing authorisation holder only; how to report a defect with a veterinary medicine.
Details of the improvement notice issued to Charles CBD Therapies, South Tyneside. Published 19 June 2019.
Product defect recall alert for Alfaxan and Alfaxan Multidose 10 mg/ml Solution for Injection for Dogs, Cats and Pet Rabbits – (Vm 25296/4003 and Vm 25296/4004) by Jurox UK
Details of the improvement notice issued to Mr Gilbert, Womblehill, Inverurie, Aberdeenshire
Guidance for prescribing vets on the use of the cascade.
Guidance for manufacturers and suppliers of veterinary medicines for incorporation into animal feedingstuffs.
A shockingly high number of dogs, mice, cats, rabbits and other animals are still suffering in invasive, painful and sometimes lethal experiments in British laboratories.
Encouraging early data have been seen with the studied combination, as in a Phase Ib investigator sponsored trial from Japan called REGONIVO
The antibiotics, known as class II polyketides, are also naturally produced by soil bacteria and have antimicrobial properties.
Under the terms of the deal Bridge Biotherapeutics will receive upfront and near term payments of EUR 45million and is eligible to receive up to more than EUR 1.1billion in potential payments.
ALS is a progressive neurodegenerative disease that affects motor neuron cells in the brain and the spinal cord.
The governing body accepted the company's Biologics License Application for prevention of vaso-occlusive crises.
More than 85% of companies have no women executives on their main boards, only 9% of executive directors on main boards are women, and a mere 17% of FTSE350 executive committee members are women.
During the pilot over the last seven months over 1,000 customers accessed the service, with the majority of them completing the service in the same day.
The Mitomic Prostate Test has a 92% sensitivity, which means that men with a positive result can be referred for immediate medical intervention.
The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies.
AMAL’s lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month.
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments.
NICE has recommended Novartis’ Kisqali just three months after its initial rejection.
The ‘toolkit’, will be available to help companies implement the FAIR guiding principles for data management and stewardship.
A new ‘transfer window’ lets staff move within the NHS between areas while developing new skills.
Unit 2 Fleet Business Park, Sandy Lane, Church Crookham, Fleet, Hampshire, GU52 8BF
Pharmaceutical and Veterinary Licensed Distributor. WDA (H) 43703 & WDA (V) 43703.
- +44 (0)1252 260 460.
- +44 (0)1276 469 290
Monday to Friday - 09:30 – 18:30
Saturday & Sunday - Closed, Online Ordering Available
